Corona Remedies
- Market cap
- ₹ 12,330 Cr.
- P/E
- 63.4x
- P/B
- 16.74x
- 52-week range
- 1,336.6 – 2,292.4
- ROE
- 30%
- ROCE
- 33%
- Dividend yield
- 0.5%
- Debt / equity
- 0.22
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Corona Remedies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)63.4 against a typical 34.3: pricier than most peers (1st = cheapest).169th of 220
- Sales growth+21.6% against a typical +15.6% from a year earlier.76th of 197
- Profit growth+30.4% against a typical +18.9% from a year earlier.70th of 160
- Share price, 3 months+5.7% against a typical 0%.79th of 200
- Size₹ 12,330.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).38th of 199
Latest announcements
Exchange filings and their impact on the company.
- ANVISA GMP approval for two Ahmedabad plants opens Brazil export door, with only small near-term sales lift.
Corona Remedies has received GMP compliance certification from Brazil's health regulator ANVISA for its oral solid dose and hormone manufacturing facilities at Bhayla, Ahmedabad. The approval certifies the plants meet Brazilian manufacturing standards and is required to export medicines to Brazil. It opens a new export market for the company, though actual sales will depend on product registrations and partnerships and are likely to build up gradually.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A+ | Stable | 9 Oct 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 9 Oct 2026 | Reaffirmed | CARE A+ | — | CARE | ₹ 77 Cr. | |
| 9 Feb 2026 | Reaffirmed | CARE A+ | — | CARE | ₹ 95 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 31 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 11 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2026. |
| 2 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 2 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other Income | 2 | 1 | 1 | 2 | 2 | −17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 43 | 61 | 70 | 55 | 54 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net Profit | 43 | 45 | 31 | 46 | 52 | 41 | 45 | 60 |
| EPS in Rs | 7.03 | 7.32 | 5.12 | 7.59 | 8.53 | 6.74 | 7.37 | 9.83 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 19%
- 3 Years
- 17%
- TTM
- 18%
- 10 Years
- —
- 5 Years
- 23%
- 3 Years
- 33%
- TTM
- 28%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 22%
- 3 Years
- 26%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Corona Remedies | ₹ 2,210.00 | ₹ 12,330 Cr. | 63.4x | 16.7x | 30% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Niravkumar Kirtikumar Mehta
- Chief Executive Officer, Managing Director, Whole Time Director
- Bhavin Nareshbhai Bhagat
- Chief Financial Officer
- Chetna Prabhat Kumar Dharajiya
- Compliance Officer, Company Secretary
- Ankur Kirtikumar Mehta
- Joint Managing Director, Whole Time Director
- Viral Bhupendrabhai Sitwala
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.